These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 40676)

  • 21. The effect of different types of cortical lesions on drug-induced catalepsy in rats: a pharmacological analysis.
    Worms P; Willigens MT; Continsouza-Blanc D; Lloyd KG
    Eur J Pharmacol; 1985 Jul; 113(1):53-9. PubMed ID: 2864264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats.
    Agovic MS; Yablonsky-Alter E; Lidsky TI; Banerjee SP
    Eur J Pharmacol; 2008 Jun; 587(1-3):181-6. PubMed ID: 18457824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
    Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
    Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol.
    Umathe SN; Wanjari MM; Manna SS; Jain NS
    Neuropeptides; 2009 Jun; 43(3):251-7. PubMed ID: 19403167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase of dopamine synthesis in synaptosomes from rats treated with neuroleptics or reserpine.
    Tissari AH
    Med Biol; 1982 Feb; 60(1):38-41. PubMed ID: 6121960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Arousal inhibiting and catalepsy in neuroleptic drugs].
    Stille G
    Arzneimittelforschung; 1966 Feb; 16(2):255-6. PubMed ID: 6013811
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats.
    See RE; Chapman MA; Meshul CK
    Synapse; 1992 Oct; 12(2):147-54. PubMed ID: 1362290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [EXPERIMENTAL EQUIVALENTS OF THE NEUROLOGIC SYNDROME OF NEUROLEPTICS].
    BOISSIER JR; SIMON P
    Encephale; 1964; 53():SUPPL:109-22. PubMed ID: 14161523
    [No Abstract]   [Full Text] [Related]  

  • 29. Studies on the mechanism of postetorphine catalepsy. Effects of clotiapine, haloperidol and rompun on postetorphine changes in concentrations of dopamine and noradrenaline in central nervous system of rats.
    Kania BF
    Acta Physiol Pol; 1980; 31(1):9-16. PubMed ID: 6103632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing time-dependent tolerance of catalepsy by repetitive administration of haloperidol in mice.
    Viyoch J; Ohdo S; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2001 Sep; 298(3):964-9. PubMed ID: 11504791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Des-1-tyrosine-gamma-endorphin: an assessment of its neuroleptic properties and effect on dopamine synthesis].
    Raevskiĭ KS; Shemanov AIu; Kudrin VS
    Farmakol Toksikol; 1982; 45(5):5-8. PubMed ID: 6128254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of antihistamine drugs on the neuroleptic-induced catalepsy.
    Pawłowski L; Sidorowicz L
    Pol J Pharmacol Pharm; 1978; 30(5):665-73. PubMed ID: 35784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The action of neuroleptics on different types of catalepsy in rats with a genetic predisposition to catatonic reactions].
    Kolpakov VG; Nikulina EM; Alekhina TA; Gevorgian MM
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1995; 45(2):388-94. PubMed ID: 7597835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticataleptic effect of taurine: interaction with antiparkinsonian agents.
    Zebrowska-Lupina I; Porowska A
    Pol J Pharmacol Pharm; 1987; 39(4):329-35. PubMed ID: 2897118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGYT-2509 a novel neuroleptic agent without extrapyramidal and endocrine side effects.
    Gacsályi I; Petöcz L; Fekete MI; Bükkfálvi B; Görgenyi F; Arató M
    Pol J Pharmacol Pharm; 1988; 40(6):613-9. PubMed ID: 2908364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison between some biochemical and behavioural effects produced by neuroleptics.
    Fregnan GB; Porta R
    Arzneimittelforschung; 1981; 31(1):70-4. PubMed ID: 6111328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol].
    Kikumoto O; Okamoto Y; Hayakawa H; Yokota N; Kawai K; Motohashi N; Yamawaki S
    Yakubutsu Seishin Kodo; 1993 Feb; 13(1):39-42. PubMed ID: 7686319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacologic profile of n-palmitoylglycine. Its effect on reserpine and haloperidol catalepsy].
    Vamvakidès A
    Boll Chim Farm; 1995 May; 134(5):258-62. PubMed ID: 7546535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nicotine potentiates the behavioral effects of haloperidol.
    Emerich DF; Norman AB; Sanberg PR
    Psychopharmacol Bull; 1991; 27(3):385-90. PubMed ID: 1775613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912.
    Coward DM; Dixon AK; Urwyler S; White TG; Enz A; Karobath M; Shearman G
    J Pharmacol Exp Ther; 1990 Jan; 252(1):279-85. PubMed ID: 1967646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.